Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Platinum-based Doublet Chemotherapy plus Bevacizumab Without Bevacizumab Maintenance in Advanced Non-small Cell Lung Cancer (NSCLC)

DORTE SCHOU NØRØXE, SANDRA WALLEREK and JENS BENN SØRENSEN
Anticancer Research August 2013, 33 (8) 3275-3278;
DORTE SCHOU NØRØXE
Department of Oncology, Finsen Centre/National University Hospital, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dnoroxe{at}dadlnet.dk
SANDRA WALLEREK
Department of Oncology, Finsen Centre/National University Hospital, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JENS BENN SØRENSEN
Department of Oncology, Finsen Centre/National University Hospital, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 33 no. 8 3275-3278
PMID 
23898091

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received May 29, 2013
  • Revision received June 28, 2013
  • Accepted July 1, 2013
  • Published online July 29, 2013.

Copyright & Usage 
Copyright© 2013 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. DORTE SCHOU NØRØXE⇑,
  2. SANDRA WALLEREK and
  3. JENS BENN SØRENSEN
  1. Department of Oncology, Finsen Centre/National University Hospital, Copenhagen, Denmark
  1. Correspondence to: Dorte Schou Nørøxe, Tybjergvej 63, 2720 Vanløse, Denmark. Tel: +45 50573919, Fax: +45 35455389, e-mail: dnoroxe{at}dadlnet.dk
View Full Text

Statistics from Altmetric.com

Cited By...

  • 5 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 33, Issue 8
August 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Platinum-based Doublet Chemotherapy plus Bevacizumab Without Bevacizumab Maintenance in Advanced Non-small Cell Lung Cancer (NSCLC)
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Platinum-based Doublet Chemotherapy plus Bevacizumab Without Bevacizumab Maintenance in Advanced Non-small Cell Lung Cancer (NSCLC)
DORTE SCHOU NØRØXE, SANDRA WALLEREK, JENS BENN SØRENSEN
Anticancer Research Aug 2013, 33 (8) 3275-3278;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Platinum-based Doublet Chemotherapy plus Bevacizumab Without Bevacizumab Maintenance in Advanced Non-small Cell Lung Cancer (NSCLC)
DORTE SCHOU NØRØXE, SANDRA WALLEREK, JENS BENN SØRENSEN
Anticancer Research Aug 2013, 33 (8) 3275-3278;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC
  • Google Scholar

More in this TOC Section

  • Surgical and Oncologic Outcomes in Uterine Carcinosarcoma: A Retrospective Cohort Analysis
  • Clinical Utility of the Preoperative Cachexia Index in Patients Undergoing Curative Gastrectomy for Gastric Cancer
  • Efficacy of Platinum-based Chemotherapy for Platinum-sensitive Recurrent Ovarian Cancer During PARP Inhibitor Treatment: A Multicenter Retrospective Study
Show more Clinical Studies

Keywords

  • Lung cancer
  • non-small cell lung cancer
  • NSCLC
  • Bevacizumab
  • platinum-based chemotherapy
  • overall survival
  • progression-free survival
  • Brain metastases
  • humanized monoclonal antibody
  • angiogenesis
  • vascular endothelial growth factor A (VEGF-A)
  • pulmonary haemorhage
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire